|
Online View
|
|
|
|
Comprehensive Solutions for
Autoimmune Breakthroughs
|
|
|
|
In recent years, significant progress has been made in the development of therapeutics for autoimmune diseases. The FDA has approved several monoclonal antibodies and small molecule inhibitor drugs. Key drug targets in autoimmune disease research include cytokines (such as TNF-α, IL-6, IL-17, IL-23, TL1A), B cell markers (CD19, CD20), and intracellular kinases (JAK, TYK2)—all central to current and next-generation therapies. Sino Biological provides comprehensive solutions for autoimmune research, including premium cytokines (like Trimeric TL1A), HPLC-verified proteins (CD19), and active kinases (JAK)—trusted tools for cutting-edge autoimmune disease research along with research reagents for biomarker studies.
|
|
Click to Learn More about Autoimmune Disease Research Solutions 
|
|
|
|
Autoimmune Disease Research Solutions
|
|
Sino Biological provides comprehensive solutions for autoimmune research, offering target proteins, cytokines, kinases, and biomarker study reagents.
|
|
|
|
|
|
|
|
Broad Coverage of 46 Diseases
Rheumatoid arthritis, psoriasis, multiple sclerosis, etc.
|
|
Multiple Targets Available
Including immune cell targets, cytokines, and kinases.
|
|
High Quality Products
Target proteins with high activity, purity, and consistency
|
|
|
Learn More Our Solutions
|
|
|
|
Featured Products
|
|
Target Protein: CD19
|
|
Cytokine: TL1A
|
|
Human CD19 Protein, HPLC-verified
Cat#: 11880-H02W
|
|
Human TL1A/TNFSF15 Protein, MALS-verified
Cat#: 17049-H07H2
|
|
|
|
|
|
Immobilized Recombinant Human CD19 Protein (ECD, Fc Tag) (Cat#: 11880-H02W) at 2 μg/mL (100 μL/well) can bind Anti-Human CD19 Antibody (IgG1) (Routinely tested).
|
|
Immobilized Anti-TNFSF15 (Research Grade Tulisoki*art Biosimilar) at 2 μg/mL (100 μL/well) can bind Recombinant Human TL1A/TNFSF15 Protein (Routinely tested).
|
|
|
|
|
|
Protein Kinases: JAK1
|
|
Biomarker: IL-6
|
|
Human JAK1 Protein (GST Tag), Active
Cat#: J01-11G Download Protocol
|
|
Human IL-6 Protein, Tag Free
Cat#: 10395-HNAE
|
|
|
|
|
|
The specific activity of JAK1 was determined to be 8.5 nmol/min/mg as per activity assay protocol and was equivalent to 19 nmol/min/mg as per radiometric assay.
|
|
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells.
|
|
|
Click to View More Target Proteins, Cytokines, and Kinases
|
|
|
|
Don’t Miss Out!
|
|
Kinase Drug Discovery Solutions >>
|
|
Center for Bioprocessing (C4B)
US-Based Recombinant Production >>
|
|
|
|
|
|
